The validity of pediatric cancer diagnoses in a population-based general cancer registry in Ontario, Canada.
BMC Cancer. 2016.
PMID: 27842503
Free PMC article.
Search Page
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
| Year | Number of Results |
|---|---|
| 1948 | 4 |
| 1949 | 1 |
| 1950 | 5 |
| 1951 | 2 |
| 1953 | 2 |
| 1954 | 1 |
| 1955 | 2 |
| 1956 | 3 |
| 1957 | 1 |
| 1958 | 1 |
| 1960 | 1 |
| 1961 | 1 |
| 1962 | 2 |
| 1963 | 1 |
| 1964 | 4 |
| 1965 | 1 |
| 1966 | 1 |
| 1967 | 5 |
| 1968 | 5 |
| 1970 | 4 |
| 1971 | 1 |
| 1972 | 2 |
| 1973 | 5 |
| 1974 | 4 |
| 1975 | 19 |
| 1976 | 20 |
| 1977 | 13 |
| 1978 | 14 |
| 1979 | 20 |
| 1980 | 18 |
| 1981 | 15 |
| 1982 | 13 |
| 1983 | 17 |
| 1984 | 24 |
| 1985 | 24 |
| 1986 | 29 |
| 1987 | 22 |
| 1988 | 26 |
| 1989 | 28 |
| 1990 | 40 |
| 1991 | 43 |
| 1992 | 44 |
| 1993 | 42 |
| 1994 | 48 |
| 1995 | 37 |
| 1996 | 50 |
| 1997 | 55 |
| 1998 | 61 |
| 1999 | 63 |
| 2000 | 61 |
| 2001 | 80 |
| 2002 | 83 |
| 2003 | 86 |
| 2004 | 82 |
| 2005 | 78 |
| 2006 | 91 |
| 2007 | 148 |
| 2008 | 190 |
| 2009 | 186 |
| 2010 | 199 |
| 2011 | 199 |
| 2012 | 199 |
| 2013 | 264 |
| 2014 | 399 |
| 2015 | 502 |
| 2016 | 549 |
| 2017 | 588 |
| 2018 | 585 |
| 2019 | 659 |
| 2020 | 739 |
| 2021 | 746 |
| 2022 | 665 |
| 2023 | 577 |
| 2024 | 308 |
Search Results
8,087 results
Results by year
Citations
13
articles
found by citation matching
High-resolution array CGH clarifies events occurring on 8p in carcinogenesis.
BMC Cancer. 2008.
PMID: 18840272
Free PMC article.
The Initiative to Maximize Progress in Adolescent and Young Adult Cancer Therapy (IMPACT) Cohort Study: a population-based cohort of young Canadians with cancer.
BMC Cancer. 2014.
PMID: 25367402
Free PMC article.
Search results
Page 1
POLE, POLD1, and NTHL1: the last but not the least hereditary cancer-predisposing genes.
Oncogene. 2021 Oct;40(40):5893-5901. doi: 10.1038/s41388-021-01984-2. Epub 2021 Aug 6.
Oncogene. 2021.
PMID: 34363023
Review.
POLE, POLD1, and NTHL1 are involved in DNA replication and have recently been recognized as hereditary cancer-predisposing genes, because their alterations are associated with colorectal cancer and other tumors. ...Endometrial and breast cancers, and p …
POLE, POLD1, and NTHL1 are involved in DNA replication and have recently been recognized as hereditary cancer-predisposing gen …
POLE/POLD1 mutation and tumor immunotherapy.
J Exp Clin Cancer Res. 2022 Jul 2;41(1):216. doi: 10.1186/s13046-022-02422-1.
J Exp Clin Cancer Res. 2022.
PMID: 35780178
Free PMC article.
Review.
POLE/POLD1 exonuclease domain mutations lead to loss of proofreading function, which causes the accumulation of mutant genes in cells. ...This article reviews the function of POLE/POLD1, its relationship with deficient mismatch repair/high microsatellite instability …
POLE/POLD1 exonuclease domain mutations lead to loss of proofreading function, which causes the accumulation of mutant genes in cells …
Evaluation of treatment effects in patients with endometrial cancer and POLE mutations: An individual patient data meta-analysis.
Cancer. 2021 Jul 15;127(14):2409-2422. doi: 10.1002/cncr.33516. Epub 2021 Apr 1.
Cancer. 2021.
PMID: 33793971
Free article.
BACKGROUND: Endometrial cancers (ECs) with somatic mutations in DNA polymerase epsilon (POLE) are characterized by unfavorable pathological features, which prompt adjuvant treatment. ...Women who have endometrial cancers with true POLE mutations experi …
BACKGROUND: Endometrial cancers (ECs) with somatic mutations in DNA polymerase epsilon (POLE) are characterized by unfavorable …
Monocarboxylate transporters in cancer.
Mol Metab. 2020 Mar;33:48-66. doi: 10.1016/j.molmet.2019.07.006. Epub 2019 Jul 27.
Mol Metab. 2020.
PMID: 31395464
Free PMC article.
Review.
Glucose fuels glycolysis that can be coupled to the tricarboxylic acid (TCA) cycle and oxidative phosphorylation (OXPHOS) in oxidative cancer cells or to lactic fermentation in proliferating and in hypoxic cancer cells. ...This review summarizes the current knowledg …
Glucose fuels glycolysis that can be coupled to the tricarboxylic acid (TCA) cycle and oxidative phosphorylation (OXPHOS) in oxidative ca …
Adjuvant therapy for endometrial cancer in the era of molecular classification: radiotherapy, chemoradiation and novel targets for therapy.
Int J Gynecol Cancer. 2021 Apr;31(4):594-604. doi: 10.1136/ijgc-2020-001822. Epub 2020 Oct 20.
Int J Gynecol Cancer. 2021.
PMID: 33082238
Free PMC article.
Review.
For high-risk endometrial cancer, recent large randomized trials support the use of pelvic radiotherapy, especially in stage I-II endometrial cancer with risk factors. ...Recent molecular studies, most notably the work from The Cancer Genome Atlas (TCGA) proj …
For high-risk endometrial cancer, recent large randomized trials support the use of pelvic radiotherapy, especially in stage I-II end …
POLE proofreading defects: Contributions to mutagenesis and cancer.
DNA Repair (Amst). 2019 Apr;76:50-59. doi: 10.1016/j.dnarep.2019.02.007. Epub 2019 Feb 16.
DNA Repair (Amst). 2019.
PMID: 30818169
Free PMC article.
Review.
This review describes how mutations in these replication DNA polymerases help to drive mutagenesis and tumor development, with particular attention to DNA polymerase epsilon. Recent studies using cancer genome sequencing, mutational signature analyses, yeast and mouse mode …
This review describes how mutations in these replication DNA polymerases help to drive mutagenesis and tumor development, with particular at …
Incorporation of molecular characteristics into endometrial cancer management.
Histopathology. 2020 Jan;76(1):52-63. doi: 10.1111/his.14015.
Histopathology. 2020.
PMID: 31846532
Free PMC article.
Review.
Histopathological evaluation including subtyping and grading is the current cornerstone for endometrial cancer (EC) classification. This provides clinicians with prognostic information and input for further treatment recommendations. Nonetheless, patients with histological …
Histopathological evaluation including subtyping and grading is the current cornerstone for endometrial cancer (EC) classification. T …
Genetic Predisposition to Colorectal Cancer: How Many and Which Genes to Test?
Int J Mol Sci. 2023 Jan 21;24(3):2137. doi: 10.3390/ijms24032137.
Int J Mol Sci. 2023.
PMID: 36768460
Free PMC article.
Review.
Colorectal cancer is one of the most common tumors, and genetic predisposition is one of the key risk factors in the development of this malignancy. ...Moreover, the recent advances in molecular techniques, in particular Next-Generation Sequencing, have led to the identifi …
Colorectal cancer is one of the most common tumors, and genetic predisposition is one of the key risk factors in the development of t …
p53abn Endometrial Cancer: understanding the most aggressive endometrial cancers in the era of molecular classification.
Int J Gynecol Cancer. 2021 Jun;31(6):907-913. doi: 10.1136/ijgc-2020-002256. Epub 2021 Feb 15.
Int J Gynecol Cancer. 2021.
PMID: 33589443
Review.
In both systems there is a small subset of endometrial cancers (serous histotype/high numbers of somatic copy number abnormalities) that account for a disproportionately high percentage of endometrial cancer related deaths. ...Immunostaining for p53 stratifies the r …
In both systems there is a small subset of endometrial cancers (serous histotype/high numbers of somatic copy number abnormalities) t …
Impact of cancer metabolism on therapy resistance - Clinical implications.
Drug Resist Updat. 2021 Dec;59:100797. doi: 10.1016/j.drup.2021.100797. Epub 2021 Dec 16.
Drug Resist Updat. 2021.
PMID: 34955385
Free article.
Review.
Furthermore, we report the role of TME-mediated intratumoral metabolic heterogeneity in therapy resistance and how adaptations in amino acid, glucose, and lipid metabolism support the growth of therapy-resistant cancers and/or cellular subpopulations. We also report the in …
Furthermore, we report the role of TME-mediated intratumoral metabolic heterogeneity in therapy resistance and how adaptations in amino acid …
Cite